Press release Communiqué de presse
Press release Communiqué de presse
June 1, 2021 1 June, 2021
Sernova Announces American Transplant Congress 2021Virtual Connect Abstract Presentation
June 1, 2021 7:00 am ET
LONDON, ONTARIO – June 1, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a leading
clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal
investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes
clinical trial will present data and observations from the ongoing study in a presentation at the upcoming
American Transplant Congress (ATC) Virtual Connect to be held June 4 - 9, 2021.
The live presentation entitled “Islet Allotransplantation Into the Pre-Vascularized Sernova Cell PouchTM Device
- Preliminary Results from University of Chicago” will be available to conference attendees on Saturday, June 5,
2021 at 6:30pm ET.
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro-
encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device
upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the
transplantation and function of therapeutic cells, which then release proteins and hormones as required to
treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and
efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible
environment for insulin-producing cells in humans.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
ABOUT THE AMERICAN TRANSPLANT CONGRESS
The American Transplant Congress (ATC) is the joint annual Congress of the American Society of Transplant
Surgeons (ASTS) and the American Society of Transplantation (AST). ATC provides a forum for exchange of new
scientific and clinical information relevant to solid organ and tissue transplantation and brings together
transplant physicians, scientists, nurses, organ procurement personnel, pharmacists, allied health
professionals, and other transplant professionals. The educational offerings provide attendees the opportunity
to learn cutting-edge advances in research and promotes the exchange of ideas and practice in the field of solid
organ and tissue transplantation. ATC is an annual Congress that welcomes over 5,000 transplant professionals
to present cutting-edge science that covers all organ types and offers insight into the future of the field and
patient care.
ABOUT ATC 2021 VIRTUAL CONNECT
ATC 2021 Virtual Connect, is the ATC’s new, enhanced virtual meeting experience for transplantation
professionals taking place June 4-9, 2021. This year’s all-virtual format will feature a robust program of new
scientific and clinical information, discussions around care and management, and socioeconomic, ethical, and
regulatory issues relevant to organ and tissue transplantation. This year’s program will also feature new
COVID-19 content pertinent to the field of transplantation.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Investor Relations
Sernova Corp.
Tel: (519) 858-5126
Investorrelations@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.